BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+7.64%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.56B
AUM Growth
+$6.56B
(+0.3%)
Cap. Flow
-$210M
Cap. Flow
% of AUM
-3.2%
Top 10 Holdings %
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14
Top Buys
| 1 |
DexCom
DXCM
|
$42.5M |
| 2 |
Cooper Companies
COO
|
$31.6M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$17.8M |
| 4 |
SI-BONE Inc
SIBN
|
$16.6M |
| 5 |
Steris
STE
|
$16.5M |
Top Sells
| 1 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$114M |
| 2 |
Intuitive Surgical
ISRG
|
$59.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$51.7M |
| 4 |
Evolent Health
EVH
|
$29.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$28.3M |
Sector Composition
| 1 | Healthcare | 99.12% |
| 2 | Industrials | 0.77% |
| 3 | Technology | 0.02% |
| 4 | Communication Services | 0.02% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Molina Healthcare
MOH
$9.8B
| $41M | 0.63% | 99,883 +8,407 | +9% | +$3.45M |
|
52
Merck
MRK
$210B
| $41M | 0.63% | 310,851 +20,645 | +7% | +$2.72M |
|
53
Penumbra
PEN
$10.6B
| $40.4M | 0.62% | 181,158 -21,888 | -11% | -$4.88M |
|
|
54
Cooper Companies
COO
$13.4B
| $40.3M | 0.61% | 397,373 +311,336 | +362% | +$31.6M |
|
55
Beam Therapeutics
BEAM
$1.66B
| $39.4M | 0.6% | 1,193,121 +498,300 | +72% | +$16.5M |
|
56
Veeva Systems
VEEV
$44B
| $39M | 0.59% | 168,247 -26,766 | -14% | -$6.2M |
|
57
Scholar Rock
SRRK
$3.14B
| $38.5M | 0.59% | 2,165,203 -3,722 | -0.2% | -$66.1K |
|
58
Zimmer Biomet
ZBH
$21B
| $37.2M | 0.57% | 282,217 +1,129 | +0.4% | +$149K |
|
59
Fate Therapeutics
FATE
$120M
| $35.5M | 0.54% | 4,839,779 -11,800 | -0.2% | -$86.6K |
|
|
SWAV
60
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $34.4M | 0.53% | 105,786 -19,024 | -15% | -$6.19M |
|
61
Sarepta Therapeutics
SRPT
$1.78B
| $32.6M | 0.5% | 251,521 +14,235 | +6% | +$1.84M |
|
62
Cencora
COR
$56.5B
| $32M | 0.49% | 131,504 +5,378 | +4% | +$1.31M |
|
63
Globus Medical
GMED
$8.27B
| $31.1M | 0.47% | 579,898 -27,874 | -5% | -$1.5M |
|
64
Cigna
CI
$80.3B
| $28.9M | 0.44% | 79,645 -8,825 | -10% | -$3.21M |
|
65
Centene
CNC
$14.3B
| $28.5M | 0.43% | 363,100 -78,753 | -18% | -$6.18M |
|
66
BioMarin Pharmaceuticals
BMRN
$11.2B
| $28.1M | 0.43% | 321,787 -3,989 | -1% | -$348K |
|
67
Apellis Pharmaceuticals
APLS
$3.48B
| $27.9M | 0.42% | 473,915 -347,885 | -42% | -$20.4M |
|
|
SILK
68
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $27.8M | 0.42% | 1,518,230 +82,548 | +6% | +$1.51M |
|
69
Castle Biosciences
CSTL
$696M
| $27M | 0.41% | 1,220,085 -12,293 | -1% | -$272K |
|
70
Transmedics
TMDX
$3.92B
| $26.9M | 0.41% | 364,064 -154,826 | -30% | -$11.4M |
|
71
Esperion Therapeutics
ESPR
$448M
| $26.7M | 0.41% | 9,944,064 +5,739,800 | +137% | +$15.4M |
|
72
Wave Life Sciences
WVE
$1.53B
| $25.3M | 0.39% | 4,094,458 -400,000 | -9% | -$2.47M |
|
73
Natera
NTRA
$23.1B
| $24.7M | 0.38% | 269,832 +13,248 | +5% | +$1.21M |
|
74
Thermo Fisher Scientific
TMO
$186B
| $23.2M | 0.35% | 39,956 +4,614 | +13% | +$2.68M |
|
75
Hologic
HOLX
$14.9B
| $22.6M | 0.34% | 289,969 +105 | +0% | +$8.19K |
|